Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER vs AMINOSOL 5%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TRAVASOL 4.25% IN DEXTROSE 25% provides crystalline amino acids and dextrose for parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a carbohydrate source for energy. The formulation supplies essential and nonessential amino acids to maintain nitrogen balance and support tissue repair and growth.
Aminosyl 5% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance in patients unable to tolerate enteral feeding.
Total parenteral nutrition (TPN) in patients who cannot tolerate adequate oral or enteral nutrition,Peripheral parenteral nutrition (PPN) when central venous access is not available
Total parenteral nutrition in patients with inadequate oral or enteral intake,Correction of negative nitrogen balance in malnourished patients
Intravenous infusion; usual adult dose provides 0.5-2.0 g amino acids/kg/day, with dextrose providing 2-5 mg/kg/min; rate adjusted according to metabolic and fluid needs; typically infused over 24 hours via central line.
Intravenous infusion: 500 m L to 1 L of 5% solution over 8-12 hours, providing 25-50 g of amino acids. Maximum infusion rate: 0.1 g/kg/hour. Dose based on metabolic requirements and clinical status.
Not applicable as TRAVASOL 4.25% IN DEXTROSE 25% is a nutrient solution, not a drug with a defined elimination half-life.
The half-life of infused amino acids is not defined as they are endogenous compounds. However, the nitrogen from amino acids has a biological half-life of approximately 6-18 hours, depending on metabolic activity. As part of total parenteral nutrition, the elimination half-life of infused amino acids is influenced by protein turnover and catabolism.
Amino acids undergo deamination and transamination in the liver; dextrose is metabolized via glycolysis and the citric acid cycle; insulin secretion increases in response to dextrose.
Amino acids are metabolized primarily in the liver via transamination, deamination, and urea cycle. Excretion of nitrogenous waste as urea occurs renally.
The amino acids and dextrose are completely metabolized; no significant renal or biliary excretion of intact product.
Excretion of infused amino acids is primarily renal, with small amounts lost via feces and skin. Approximately 85-95% of the nitrogen load is excreted in urine as urea, ammonia, and other nitrogenous wastes. Less than 5% is eliminated in feces.
Not applicable; amino acids and dextrose do not bind to plasma proteins.
Amino acids are not protein-bound; they exist free in plasma. Minimal reversible binding to albumin occurs for some amino acids, but overall binding is <10%.
Not applicable; distributes throughout total body water.
The volume of distribution for amino acids is approximately 0.3-0.4 L/kg, reflecting distribution primarily in extracellular fluid and to a lesser extent intracellularly.
Intravenous: 100% bioavailable.
Intravenous: 100% bioavailability. Not administered via other routes; oral or enteral administration is not applicable due to hepatic first-pass metabolism and different pharmacokinetics.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 50% or monitor BUN and creatinine; GFR <10 m L/min: avoid unless on dialysis; adjust based on nitrogen balance and fluid status.
In GFR < 50 m L/min: reduce infusion rate by 50% and monitor nitrogen balance. In ESRD on dialysis: use only if essential; typical dose 0.5-0.6 g/kg/day of amino acids with careful monitoring.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor ammonia; Child-Pugh C: avoid use due to risk of encephalopathy from amino acid load.
Contraindicated in severe hepatic failure (Child-Pugh C) due to risk of hepatic encephalopathy. In Child-Pugh A or B, use with caution and reduce dose by 30-50%; monitor ammonia levels.
Neonates and infants: initial 0.5-1 g amino acids/kg/day, increase gradually to 2-3 g/kg/day; dextrose initial 4-6 mg/kg/min, titrate up to 12-15 mg/kg/min; continuous infusion via central vein.
Infants and children: 1-2 g/kg/day of amino acids via total parenteral nutrition (TPN) as a 5% solution. Adjust based on age, weight, and clinical condition. Maximum infusion rate 0.1 g/kg/hour.
Start at lower end of dose range (0.5-1 g amino acids/kg/day); monitor fluid and electrolyte balance closely; adjust for renal function and comorbidities; rate reduction may be needed due to decreased metabolic reserve.
Start at lower end of dosing; monitor renal function (creatinine clearance) and avoid fluid overload. Typical initial dose: 0.8-1 g/kg/day of amino acids, adjusted to tolerance and clinical response.
None (not FDA-approved, but similar parenteral nutrition products carry warnings for metabolic complications, including hyperglycemia, hyperosmolar coma, and electrolyte imbalances; use in patients with severe renal or hepatic disease may require dose adjustments).
None.
Risk of hyperglycemia, hyperosmolar hyperglycemic state, and rebound hypoglycemia if infusion is stopped abruptly,Monitor serum electrolytes, blood urea nitrogen (BUN), glucose, and liver function tests regularly,Use with caution in patients with renal insufficiency (may require protein restriction), hepatic failure, or metabolic disorders (e.g., maple syrup urine disease),Potential for infection and thrombophlebitis with central venous access,Do not administer if solution is discolored or contains particulate matter
Use with caution in patients with renal impairment (risk of azotemia and electrolyte imbalances),Monitor serum electrolytes, blood glucose, and fluid balance regularly,Risk of hyperglycemia in diabetic patients; adjust insulin accordingly,Possible hyperammonemia, especially in patients with hepatic insufficiency,Contains aluminum; may accumulate in renal impairment, leading to osteomalacia or neurotoxicity
Known hypersensitivity to any component,Severe hyperglycemia or hyperosmolar state,Uncontrolled metabolic acidosis,Anuria or severe renal impairment (unless dialyzed),Inborn errors of amino acid metabolism (e.g., maple syrup urine disease),Severe hepatic insufficiency with encephalopathy
Severe hepatic failure with encephalopathy,Severe uremia without dialysis,Inborn errors of amino acid metabolism,Hypersensitivity to any component
None; parenteral nutrition bypasses the gastrointestinal tract. However, monitor blood glucose if patient is on oral hypoglycemics or insulin.
No direct food interactions as Aminos 5% is administered intravenously. However, oral dietary intake must be coordinated with total parenteral nutrition to avoid excessive protein or electrolyte intake.
Travasol 4.25% in Dextrose 25% is a parenteral nutrition solution. No specific teratogenic effects are documented; risks are related to underlying maternal malnutrition. Dextrose may cause fetal hyperinsulinemia and hypoglycemia if maternal glucose levels are high. Use only if clearly needed.
Aminosol 5% is a crystalline amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with Aminosol 5%. Therefore, the teratogenic risk is not well defined. However, as a component of parenteral nutrition, it is considered essential for maternal and fetal health when indicated. Use only if clearly needed, weighing potential benefits against unknown risks. No specific trimester-associated risks have been reported.
Not excreted into milk in significant amounts; ingredients are normal nutrients. Compatible with breastfeeding. M/P ratio not applicable.
Aminosolic 5% is a mixture of amino acids naturally present in human milk. Administration to lactating women may result in excretion of amino acids into breast milk, but the amounts are unlikely to be clinically significant. The M/P ratio is not known. Caution is advised, but use is generally considered compatible with breastfeeding when clinically indicated.
No standard dose adjustment. Monitor glucose levels closely; insulin requirements may increase due to dextrose load. Adjust infusion rate based on metabolic tolerance.
Standard adult dosing (5% solution, 500-1000 m L/day) may be used; however, increased fluid volume and metabolic demands in pregnancy may require dose adjustments. Monitor for fluid overload and adjust infusion rate accordingly. No specific dose adjustment recommendations are established; use caution and individualize based on clinical status.
This is a hypertonic solution (4.25% amino acids + 25% dextrose) used for peripheral parenteral nutrition; monitor for phlebitis due to high osmolality (>1000 m Osm/L); requires central venous access for long-term use; check serum electrolytes, glucose, and renal function daily; avoid abrupt discontinuation to prevent rebound hypoglycemia; contraindicated in patients with severe hyperglycemia, azotemia, or lipid metabolism disorders.
Aminos 5% is a crystalline amino acid solution used for parenteral nutrition. In renal failure, adjust dose to limit nitrogen load; monitor BUN. In hepatic encephalopathy, consider branched-chain amino acid formulations. Do not administer concurrently with blood products through same IV line due to risk of agglutination. Infuse via central line if peripheral veins insufficient; peripheral administration requires adequate lipid-based calorie co-administration to prevent phlebitis.
This solution is given through a vein to provide nutrition when you cannot eat normally.,Report any pain, redness, or swelling at the infusion site immediately.,You may need regular blood tests to monitor your blood sugar, kidney function, and electrolytes.,Do not stop the infusion suddenly without medical advice, as this may cause low blood sugar.,Inform your healthcare provider if you have diabetes, kidney disease, or any allergies.
This solution provides essential building blocks (amino acids) for protein synthesis when you cannot eat.,Report any signs of infection at the IV site: redness, swelling, pain, or drainage.,Tell your doctor if you experience nausea, vomiting, or headache; dose adjustment may be needed.,Do not abruptly stop this infusion; it is part of your total nutrition plan.,Regular blood tests will be required to monitor kidney and liver function.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER vs AMINOSOL 5%, answered by our medical review team.
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by TRAVASOL 4.25% IN DEXTROSE 25% provides crystalline amino acids and dextrose for parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a carbohydrate source for energy. The formulation supplies essential and nonessential amino acids to maintain nitrogen balance and support tissue repair and growth.. AMINOSOL 5% is a Parenteral Nutrition Solution that works by Aminosyl 5% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance in patients unable to tolerate enteral feeding.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER and AMINOSOL 5% depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER is: Intravenous infusion; usual adult dose provides 0.5-2.0 g amino acids/kg/day, with dextrose providing 2-5 mg/kg/min; rate adjusted according to metabolic and fluid needs; typically infused over 24 hours via central line.. The standard adult dose of AMINOSOL 5% is: Intravenous infusion: 500 m L to 1 L of 5% solution over 8-12 hours, providing 25-50 g of amino acids. Maximum infusion rate: 0.1 g/kg/hour. Dose based on metabolic requirements and clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER and AMINOSOL 5% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER is classified as Category C. Travasol 4.25% in Dextrose 25% is a parenteral nutrition solution. No specific teratogenic effects are documented; risks are related to underlying maternal malnutrition. Dextrose m. AMINOSOL 5% is classified as Category C. Aminosol 5% is a crystalline amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies hav. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.